Drug Trial Radar · NCT07742956
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Aug 20, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ALK201 for Injection combined with Ivonescimab Injection in adult patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) who are FGFR2b-positive, EGFR mutation-negative, and ALK-negative. The study consists of two parts: Part A (dose escalation) and Part B (dose optimization). Part A Dose Escalation Stage: This stage includes three dose levels. Eligible patients with locally advanced or metastatic sqNSCLC who have failed standard therapy will be enrolled to complete DLT assessment. Part B Dose Optimization Stage: This stage comprises two cohorts, enrolling eligible patients with locally advanced or metastatic sqNSCLC satisfying the respective cohort criteria: Primary cohort: PD-L1 expression ≥1% Exploratory cohort: PD-L1 expression \<1%
Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
ALK201 for injectionDrug
Subjects will be randomized 1:1 to the two dose levels selected from Part A. The administered dose will be calculated based on the assigned dose arm and the subject's body weight.
Ivonescimab InjectionDrug
The administered dose will be calculated based on a fixed dose of 20 mg/kg and the subject's body weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- TEAEsTime frame: Up to 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.